Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660466 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2PRKCI | |
| SCHEMBL15155025 | 0.98 | MGAM (0.34) | MGAMGAASIMGAM2PRKCI | |
| SCHEMBL15155026 | 0.97 | MGAM (0.33) | MGAMGAASIMGAM2PRKCI | |
| SCHEMBL15170720 | 0.85 | MGAM (0.34) | MGAMGAASIMGAM2PRKCI | |
| SCHEMBL15280118 | 0.81 | CCR1 (0.38) | — | |
| SCHEMBL29378331 | 0.80 | ENPP3 (0.36) | PRKCI | |
| SCHEMBL2794776 | 0.80 | — | — | |
| SCHEMBL29660486 | 0.80 | — | — | |
| SCHEMBL1002153 | 0.80 | — | — | |
| SCHEMBL306515 | 0.80 | ENPP3 (0.36) | PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406856-A1 | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-116554170-A | Preparation method of 4-fluoro-7-azaindole | 上海大学 | 2023-08-08 | — | — | CN | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| EP-4034108-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746090-A | Azaindole carboxamide compounds for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-113727975-A | Substituted pyrrolopyridines as JAK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| EP-1539763-A4 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1539763-A1 | AZAINDOLE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | MGAM 3969/4885GAA 3221/4885SI 1213/4885 |
| US-20230406856-A1 | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | BTK, PTK2B, SYK | MGAM 3976/4885GAA 3471/4885SI 4469/4885 |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | MGAM 4854/4885GAA 1834/4885SI 4449/4885 |
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | MGAM 4070/4885GAA 1429/4885SI 4162/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | MGAM 4854/4885GAA 1834/4885SI 4449/4885 |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | MGAM 4224/4885GAA 2233/4885SI 4729/4885 |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | MGAM 677/4885GAA 379/4885SI 1124/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | MGAM 4096/4885GAA 1485/4885SI 4177/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | MGAM 2603/4885GAA 1753/4885SI 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.